Patient-Reported Outcomes Among Virally Suppressed People Living with HIV Switching to Dolutegravir/Lamivudine vs. Continuing Bictegravir/Emtricitabine/Tenofovir Alafenamide from the Randomized DYAD Study
Open Access
- 29 September 2026
- journal article
- research article
- Published by Springer Nature in AIDS and Behavior
- p. 1-9
Abstract
No abstract availableKeywords
Funding Information
- ViiV Healthcare (214240)
This publication has 11 references indexed in Scilit:
- Changes in cerebral function parameters in persons with HIV with symptoms of insomnia switching from dolutegravir- to bictegravir-based antiretroviral therapyJournal of NeuroVirology, 2025
- Health care provider– and patient-reported outcomes for bictegravir/emtricitabine/tenofovir alafenamide versus other antiretroviral regimens: an observational survey in the United States (July 2021–March 2022)Current Medical Research and Opinion, 2025
- P-537. PAIRED - PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine (DTG/3TC): a diverse sample of people with HIV-1 reporting high treatment satisfaction, good adherence, and high quality of lifeOpen Forum Infectious Diseases, 2025
- Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD StudyOpen Forum Infectious Diseases, 2024
- Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA StudyAIDS and Behavior, 2024
- Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real‐world insights from BICSTaR cohortsHIV Medicine, 2023
- Patient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamideJournal of Microbiology, Immunology and Infection, 2023
- Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and LamivudineThe Patient - Patient-Centered Outcomes Research, 2018
- Validation of the Revised 10-Item HIV Treatment Satisfaction Questionnaire Status Version and New Change VersionValue in Health, 2006
- Development and validation of a self-completed HIV symptom indexJournal of Clinical Epidemiology, 2001